FR3107897B1 - Dérivés de nicotinamide mononucléotides - Google Patents

Dérivés de nicotinamide mononucléotides Download PDF

Info

Publication number
FR3107897B1
FR3107897B1 FR2002267A FR2002267A FR3107897B1 FR 3107897 B1 FR3107897 B1 FR 3107897B1 FR 2002267 A FR2002267 A FR 2002267A FR 2002267 A FR2002267 A FR 2002267A FR 3107897 B1 FR3107897 B1 FR 3107897B1
Authority
FR
France
Prior art keywords
nicotinamide mononucleotide
mononucleotide derivatives
derivatives
nicotinamide
arrhythmia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2002267A
Other languages
English (en)
Other versions
FR3107897A1 (fr
Inventor
Guillaume Bermond
Laurent Garçon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuvamid SA
Original Assignee
Nuvamid SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR2002267A priority Critical patent/FR3107897B1/fr
Application filed by Nuvamid SA filed Critical Nuvamid SA
Priority to PCT/EP2021/055676 priority patent/WO2021176093A1/fr
Priority to EP21709040.6A priority patent/EP4114408A1/fr
Priority to JP2022553059A priority patent/JP2023517541A/ja
Priority to CN202180019077.1A priority patent/CN115605210A/zh
Priority to CA3170031A priority patent/CA3170031A1/fr
Priority to US17/908,337 priority patent/US20230097603A1/en
Priority to AU2021231328A priority patent/AU2021231328A1/en
Publication of FR3107897A1 publication Critical patent/FR3107897A1/fr
Application granted granted Critical
Publication of FR3107897B1 publication Critical patent/FR3107897B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

DÉRIVÉS DE NICOTINAMIDE MONONUCLÉOTIDES La présente invention concerne un composé de formule (I) ou un sel et/ou solvate pharmaceutiquement acceptable de celui-ci ; (I) dans lequel X, R1, R2, R3, R4, R5, R6, R7, R8, Y, et sont tels que décrits dans les revendications, pour son utilisation dans le traitement et/ou la prévention de l’arythmie.
FR2002267A 2020-03-06 2020-03-06 Dérivés de nicotinamide mononucléotides Active FR3107897B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR2002267A FR3107897B1 (fr) 2020-03-06 2020-03-06 Dérivés de nicotinamide mononucléotides
EP21709040.6A EP4114408A1 (fr) 2020-03-06 2021-03-05 Dérivés de nicotinamide mononucléotide et de bis-nicotinamide dinucléotide pour le traitement de l'arythmie
JP2022553059A JP2023517541A (ja) 2020-03-06 2021-03-05 不整脈の治療のためのニコチンアミドモノヌクレオチド誘導体
CN202180019077.1A CN115605210A (zh) 2020-03-06 2021-03-05 用于治疗心律失常的烟酰胺单核苷酸和双烟酰胺二核苷酸衍生物
PCT/EP2021/055676 WO2021176093A1 (fr) 2020-03-06 2021-03-05 Dérivés de nicotinamide mononucléotide et de bis-nicotinamide dinucléotide pour le traitement de l'arythmie
CA3170031A CA3170031A1 (fr) 2020-03-06 2021-03-05 Derives de nicotinamide mononucleotide et de bis-nicotinamide dinucleotide pour le traitement de l'arythmie
US17/908,337 US20230097603A1 (en) 2020-03-06 2021-03-05 Nicotinamide mononucleotide derivatives for the treatment of arrhythmia
AU2021231328A AU2021231328A1 (en) 2020-03-06 2021-03-05 Nicotinamide mononucleotide derivatives for the treatment of arrhythmia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2002267A FR3107897B1 (fr) 2020-03-06 2020-03-06 Dérivés de nicotinamide mononucléotides
FR2002267 2020-03-06

Publications (2)

Publication Number Publication Date
FR3107897A1 FR3107897A1 (fr) 2021-09-10
FR3107897B1 true FR3107897B1 (fr) 2023-05-26

Family

ID=70614192

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2002267A Active FR3107897B1 (fr) 2020-03-06 2020-03-06 Dérivés de nicotinamide mononucléotides

Country Status (8)

Country Link
US (1) US20230097603A1 (fr)
EP (1) EP4114408A1 (fr)
JP (1) JP2023517541A (fr)
CN (1) CN115605210A (fr)
AU (1) AU2021231328A1 (fr)
CA (1) CA3170031A1 (fr)
FR (1) FR3107897B1 (fr)
WO (1) WO2021176093A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117304242A (zh) * 2020-12-18 2023-12-29 努瓦米德股份有限公司 烟酰胺单核苷酸衍生物及其在治疗和预防红细胞病症中的用途
WO2022263625A1 (fr) * 2021-06-17 2022-12-22 Nuvamid Sa Dérivés mononucléotidiques nicotinamides et leur utilisation pour le traitement de l'insuffisance cardiaque à fraction d'éjection préservée
CN116987064B (zh) * 2023-08-04 2024-01-26 宁夏佰斯特医药化工有限公司 一种嘧啶双烟酰胺衍生物的制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016016071A (es) * 2014-06-06 2017-07-11 Glaxosmithkline Intellectual Property (No 2) Ltd Analogos de ribosido de nicotinamida y composiciones farmaceuticas y usos de los mismos.
US9855289B2 (en) * 2015-08-05 2018-01-02 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
EP3478297A1 (fr) * 2016-06-30 2019-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement de cardiomyopathies
US11071747B2 (en) * 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
EP3765010A2 (fr) * 2018-03-13 2021-01-20 Nuchido Limited Méthode de traitement

Also Published As

Publication number Publication date
EP4114408A1 (fr) 2023-01-11
JP2023517541A (ja) 2023-04-26
CA3170031A1 (fr) 2021-09-10
FR3107897A1 (fr) 2021-09-10
WO2021176093A1 (fr) 2021-09-10
AU2021231328A1 (en) 2022-09-15
US20230097603A1 (en) 2023-03-30
CN115605210A (zh) 2023-01-13

Similar Documents

Publication Publication Date Title
FR3107897B1 (fr) Dérivés de nicotinamide mononucléotides
MX2022001671A (es) Sales de un inhibidor de pd-1/pd-l1.
MA32231B1 (fr) Composés organiques
MA46038B1 (fr) Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale
MA41338A (fr) Composés de pyrazine pour le traitement de maladies infectieuses
MA42795A (fr) Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih
MA42292B1 (fr) Dérivés de sulfamoylarylamide cyclisés et leur utilisation à titre de médicaments pour le traitement de l'hépatite b
EA202190116A1 (ru) Агент для профилактики или лечения спинальной мышечной атрофии
CR20200588A (es) Compuestos novedosos
MX2020001776A (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
MA41134A (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
JOP20220247A1 (ar) مثبطات كرومينون تفارغية لفوسفوينوسيتيد 3 كيناز (pi3k) لعلاج أمراض مرتبطة بتعديل p13k
MA32965B1 (fr) Derives de sulfonamides
MA27990A1 (fr) Derives de piperazine pour le traitement d'infections par le vih
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
MA42341B2 (fr) Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale
MA45020A (fr) Dérivés sulfonamides aromatiques
MA29926B1 (fr) Derives de pyrazine
MA46101A (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
TNSN07022A1 (fr) Derives de pyridine
MA30403B1 (fr) Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques
JP2016518437A5 (fr)
AR087046A2 (es) Compuestos derivados de 4-oxoquinolina
MA49127B1 (fr) Dérivés d'indole n-substitués
MA49956B1 (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20210910

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5